The adverse prognostic impact of HMGCLL1 gene variants can be abrogated by frontline second-generation tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

View at publisher Summarise with VIRAT
Authors: Maria Agustina Perusini, Kátia Bórgia Barbosa Pagnano, Carolina Pavlovsky, Daniela Žáčková, Jiří Mayer, Beatriz Moiraghi, Ana Inés Varela, Michele Bianchini, Ana Beatriz Pascoal Lopes, G. M. Duarte, C. de Souza, Ivana Ježíšková
+7 more Anežka Kvetková, Tomáš Jurček, Hye Won Lee, Myung Hee Chang, Jessie J.F. Medeiros, Sagi Abelson, Dennis Dong Hwan Kim
Cited by: 0
References: 15

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Fields of Study & Subjects

Chronic Myeloid Leukemia Treatments Chronic Lymphocytic Leukemia Research Acute Myeloid Leukemia Research

Publication details

Journal / source
Leukemia
Volume
40
Issue
5
Pages
1080–1082
Publication date
30 March 2026
Language
EN